Braveheart Investment Group (AIM: BRH ) said its investee company, Pharm2Farm ("P2F"), will launch the sale of a new antiviral face mask that can kill COVID-19 by the end of 2020.
The surgical mask project commenced in June and follows P2F’s development of a textile coating incorporating proprietary nanoparticles to grant long lasting virucidal properties.
The first application of this technology has been to coat a fabric layer in surgical masks and produce a certified antiviral mask for both healthcare professionals and the public.
P2F received test results from two independent laboratories confirming that the mask has a ‘kill rate’ of over 90% for up to 7 hours, meeting requirements for ISO 18184 certification which is awarded to antiviral fabrics proven to deactivate over 99% of enveloped viruses.
Shares in Braveheart Investment Group have increased in value by 88% since August 2020 to open 10.61% higher at 36.5p following the announcement.
P2F has now submitted a patent application to protect its intellectual property for the manufacturing process of the masks and its antiviral, antibacterial and antiparasitic properties.
P2F has purchased an automated mask production line which is on track to be delivered in November 2020. Manufactured in Europe, it has the capacity to produce up to five million standard or antiviral face masks per month and will be in production by the end of the year.
The investment company conditionally agreed to sell its 51.72% holding in P2F back in August 2020 to Remote Monitored Systems (LON:RMS) for 310.4m shares in the latter. On completion of the sale, Braveheart’s stake in RMS will be taken to around 37.12%.
For more news and updates on Braveheart Investment Group: